Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases

Blood

Volumn 118, Issue 11, 2011, Pages 3088-3095

  Hadzidimitriou, Anastasia ^a   Agathangelidis, Andreas ^a,b,c   Darzentas, Nikos ^a   Murray, Fiona ^d   Delfau Larue, Marie Helene ^e   Pedersen, Lone Bredo ^f   Lopez, Alba Navarro ^g   Dagklis, Antonis ^h   Rombout, Paul ⁱ   Beldjord, Kheira ^j   Kolstad, Arne ^k   Dreyling, Martin H ^l   Anagnostopoulos, Achilles ^b   Tsaftaris, Athanasios ^a   Mavragani Tsipidou, Penelope ^c   Rosenwald, Andreas ^m   Ponzoni, Maurilio ^h   Groenen, Patricia ⁱ   Ghia, Paolo ^h   Sander, Birgitta ⁿ   Papadaki, Theodora ^o   Campo, Elias ^g   Geisler, Christian ^f   Rosenquist, Richard ^d   Davi, Frederic ^p   Pott, Christiane ^q   Stamatopoulos, Kostas ^a,b   more..

^a INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^b G PAPANICOLAOU HOSPITAL   (Greece)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UPPSALA UNIVERSITY   (Sweden)

^e HENRI MONDOR HOSPITAL   (France)

^f Rigshospitalet   (Denmark)

^g UNIVERSITY OF BARCELONA   (Spain)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j HÔPITAL NECKER ENFANTS MALADES   (France)

^k OSLO UNIVERSITY HOSPITAL   (Norway)

^l LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^m UNIVERSITY OF WÜRZBURG   (Germany)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o EVANGELISMOS HOSPITAL   (Greece)

^p PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^q UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

AMINO ACID SEQUENCE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; HUMAN; IMMUNOGENETICS; IMMUNOGLOBULIN HEAVY CHAIN GENE; IMMUNOGLOBULIN HEAVY CHAIN V1 8; IMMUNOGLOBULIN HEAVY CHAIN V3 21 GENE; IMMUNOGLOBULIN HEAVY CHAIN V3 23; IMMUNOGLOBULIN HEAVY CHAIN V4 34 GENE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; SOMATIC HYPERMUTATION; STEREOTYPY;

EID: 80052929598     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-03-343434     Document Type: Article

References (47)

1. Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2009:542-551.
2. Pérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood. 2011;117(1):26-38.
3. Espinet B, Salaverria I, Bea S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer. 2010;49(5):439-451.
4. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7(10):750-762. (Pubitemid 47463673)
5. Hartmann EM, Campo E, Wright G, et al. Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood. 2010;116(6):953-961.
6. O'Connor OA. Mantle cell lymphoma: identifying novel molecular targets in growth and survival pathways. Hematology Am Soc Hematol Educ Program. 2007:270-276.
7. Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res. 2001;83:81-116. (Pubitemid 32959263)
8. Küppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5(4):251-262. (Pubitemid 40488631)
9. Murray F, Darzentas N, Hadzidimitriou A, et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood. 2008;111(3):1524-1533. (Pubitemid 351213442)
10. Dunn-Walters D, Thiede C, Alpen B, Spencer J. Somatic hypermutation and B-cell lymphoma. Philos Trans R Soc Lond B Biol Sci. 2001;356(1405):73-82. (Pubitemid 32575591)
11. Darzentas N, Hadzidimitriou A, Murray F, et al. A different ontogenesis for chronic lymphocytic leukemia cases carrying stereotyped antigen receptors: molecular and computational evidence. Leukemia. 2010;24(1):125-132.
12. Camacho FI, Algara P, Rodriguez A, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood. 2003;101(10):4042-4046. (Pubitemid 36857884)
13. Kienle D, Krober A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood. 2003;102(8):3003- 3009. (Pubitemid 37248876)
14. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975-4981. (Pubitemid 36857762)
15. Schraders M, Oeschger S, Kluin PM, et al. Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. Mod Pathol. 2009;22(3):416-425.
16. Thorsélius M, Walsh S, Eriksson I, et al. Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. Eur J Haematol. 2002;68(4):217-224. (Pubitemid 34717822)
17. Walsh SH, Thorselius M, Johnson A, et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood. 2003;101(10):4047-4054. (Pubitemid 36857885)
18. Thelander EF, Rosenquist R. Molecular genetic characterization reveals new subsets of mantle cell lymphoma. Leuk Lymphoma. 2008;49(6):1042-1049. (Pubitemid 351943249)
19. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
20. Chiorazzi N, Ferrarini M. Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. Blood. 2011;117(6):1781-1791.
21. Barbas SM, Ditzel HJ, Salonen EM, Yang WP, Silverman GJ, Burton DR. Human autoantibody recognition of DNA. Proc Natl Acad Sci U S A. 1995;92(7):2529- 2533.
22. Rahman A, Giles I, Haley J, Isenberg D. Systematic analysis of sequences of anti-DNA antibodies - relevance to theories of origin and pathogenicity. Lupus. 2002;11(12):807-823. (Pubitemid 36069977)
23. van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17(12):2257-2317. (Pubitemid 38072572)
24. Giudicelli V, Duroux P, Ginestoux C, et al. IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic Acids Res. 2006;34(Database issue):D781-784.
25. Lefranc MP, Giudicelli V, Ginestoux C, et al. IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res. 2009;37(Database issue):D1006-1012.
26. Brochet X, Lefranc MP, Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008;36(Web Server issue):W503-508.
27. Lefranc MP, Pommie C, Ruiz M, et al. IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains. Dev Comp Immunol. 2003;27(1):55-77. (Pubitemid 35449624)
28. Yousfi Monod M, Giudicelli V, Chaume D, Lefranc MP. IMGT/ JunctionAnalysis: the first tool for the analysis of the immunoglobulin and T cell receptor complex V-J and V-D-J JUNCTIONs. Bioinformatics. 2004;20 Suppl 1:i379-385.
29. Henikoff S, Henikoff JG. Performance evaluation of amino acid substitution matrices. Proteins. 1993;17(1):49-61. (Pubitemid 23261057)
30. Pommié C, Levadoux S, Sabatier R, Lefranc G, Lefranc MP. IMGT standardized criteria for statistical analysis of immunoglobulin V-REGION amino acid properties. J Mol Recognit. 2004;17(1):17-32. (Pubitemid 38231461)
31. Wu YC, Kipling D, Leong HS, Martin V, Ademokun AA, Dunn-Walters DK. High-throughput immunoglobulin repertoire analysis distinguishes between human IgM memory and switched memory B-cell populations. Blood. 2010;116(7):1070-1078.
32. Agathangelidis A DN, Hadzidimitriou A, et al. The composition of the B cell receptor repertoire in 7428 cases of chronic lymphocytic leukemia: one third stereotyped, two thirds heterogeneous - what does this mean? [abstract] Blood. 2010;116(21):25. Abstract 43.
33. Bikos V DN, Hadzidimitriou A, et al. More than 30% of patients with splenic marginal zone lymphoma express distinctive antigen receptors utilizing a single immunoglobulin variable gene: implications for the origin and selection of the neoplastic cells [abstract]. Blood. 2010;116(21):278. Abstract 634.
34. Di Noia JM, Neuberger MS. Molecular mechanisms of antibody somatic hypermutation. Annu Rev Biochem. 2007;76:1-22.
35. Barrios Y, Jirholt P, Ohlin M. Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor. J Mol Recognit. 2004;17(4):332-338. (Pubitemid 38893601)
36. Xu JL, Davis MM. Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities. Immunity. 2000;13(1):37-45.
37. Mageed RA, Harmer IJ, Wynn SL, et al. Rearrangement of the human heavy chain variable region gene V3-23 in transgenic mice generates antibodies reactive with a range of antigens on the basis of VHCDR3 and residues intrinsic to the heavy chain variable region. Clin Exp Immunol. 2001;123(1):1-8. (Pubitemid 32118829)
38. Stamatopoulos K, Belessi C, Moreno C, et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood. 2007;109(1):259-270. (Pubitemid 46070124)
39. Messmer BT, Albesiano E, Efremov DG, et al. Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. J Exp Med. 2004;200(4):519-525. (Pubitemid 39121908)
40. Chu CC, Catera R, Hatzi K, et al. Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. Blood. 2008;112(13):5122-5129.
41. Lanemo Myhrinder A, Hellqvist E, Sidorova E, et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood. 2008;111(7):3838-3848.
42. Kolar GR, Mehta D, Pelayo R, Capra JD. A novel human B cell subpopulation representing the initial germinal center population to express AID. Blood. 2007;109(6):2545-2552. (Pubitemid 46425900)
43. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005;105(11):4390-4398. (Pubitemid 40720786)
44. Lee J, Kuchen S, Fischer R, Chang S, Lipsky PE. Identification and characterization of a human CD5+ pre-naive B cell population. J Immunol. 2009;182(7):4116-4126.
45. Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal differentiation and production of natural antibodies. J Immunol. 2008;180(2):800-808.
46. Fowler N, Sharman JP, Smith S, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I study [abstract]. Blood. 2010;116(21):425. Abstract 964.
47. Furman R BJ, Brown J, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110δ demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. Blood. 2010;116(21):31. Abstract 55.